Pembelian
VVUS hits a bottom. Breaking out of falling wedge formation
- Qysmia looks to be gaining from new online marketing efforts
- Endo will start promoting Vivus' ED drug
- 36% short interest!
- Institutional investors adding at these levels
- Recently hit a 10-year-low, but things have never looked brighter for VVUS
PT: $10
Timeframe: 18 - 24 months (possibly sooner, depending on how ED drug sales are)
Disclosure: Long $2 Jan 2017 calls @1.10/contract
- Endo will start promoting Vivus' ED drug
- 36% short interest!
- Institutional investors adding at these levels
- Recently hit a 10-year-low, but things have never looked brighter for VVUS
PT: $10
Timeframe: 18 - 24 months (possibly sooner, depending on how ED drug sales are)
Disclosure: Long $2 Jan 2017 calls @1.10/contract
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.